Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
penpulimab + anlotinib + nab-paclitaxel + oxaliplatin + lobaplatin (Xijing Hospital)
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen is being evaluated in a Phase 2 randomized clinical trial at Xijing Hospital for the perioperative treatment of locally advanced resectable esophageal cancer. The regimen integrates immunotherapy, targeted therapy, and chemotherapy, consisting of **penpulimab** (an anti-PD-1 monoclonal antibody), **anlotinib** (a multi-target tyrosine kinase inhibitor), and a chemotherapy backbone of **nab-paclitaxel** (albumin-bound paclitaxel) combined with either **oxaliplatin** or **lobaplatin**. Penpulimab works by blocking the PD-1/PD-L1 pathway to restore T-cell mediated anti-tumor immunity. Anlotinib provides anti-angiogenic and anti-proliferative effects by inhibiting VEGFR, FGFR, PDGFR, and c-Kit. The chemotherapy components, nab-paclitaxel and platinum agents, induce cytotoxic effects through microtubule stabilization and DNA cross-linking, respectively. The study specifically compares the efficacy and safety of oxaliplatin versus lobaplatin within this multi-drug framework for patients with clinical stage cT2-4N0-3M0 esophageal cancer.
- Brand names
- AnnikeFocus VAbraxaneEloxatin
- Other names
- Penpulimab plus Anlotinib plus nab-paclitaxel plus Oxaliplatin or LobaplatinPenpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)
Beyond the preview
Go deeper on penpulimab + anlotinib + nab-paclitaxel + oxaliplatin + lobaplatin (Xijing Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on penpulimab + anlotinib + nab-paclitaxel + oxaliplatin + lobaplatin (Xijing Hospital).